HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Table 1 Demographics and clinicopathologic parameters for the 33 mucinous ovarian carcinoma cases identified retrospectively.

Parameter		HER2+	HER2-	p-value
Age (years)		48.0 (31-72)	51.4 (18-76)	0.62_a
Stage	I	67% (N = 4)	67% (N = 18)	0.88_b
	II	33% (N = 2)	29% (N = 8)
	III	0% (N = 0)	4% (N = 1)
Grade	1	50% (N = 3)	30% (N = 8)	0.55_b
	2	50% (N = 3)	63% (N = 17)
	3	0% (N = 0)	7% (N = 2)
Residual Disease	No	100% (N = 6)	100% (N = 27)	NR
Prior Chemotherapy	No	100% (N = 6)	100% (N = 27)	NR
Mean Progression Free Survival (years)		7.90 (3.20 -- 11.35)	5.15 (0.17 -- 20.4)	0.12_a
Mean Overall Survival (years)		7.90 (3.20 -- 11.35)	5.43 (0.35 -- 20.4)	0.16_a

Progression free survival (PFS) is defined as the time from surgery to the first clinical evidence of recurrence. Overall survival (OS) is defined as the time from surgery until death from any cause, or until the date of last follow-up. All times are given in years
a Comparisons across HER2 status computed with the Welch ANOVA test
b Comparisons across HER2 status computed with the Pearson Chi Square Statistic
NR Not reported due to equivalence

ISSN: 1471-2407